INVO Fertility, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Fertility, Inc. (Nasdaq: IVF) on October 3, 2025, covering events occurring on September 30, 2025. The filing primarily addresses the finalization of a material settlement agreement regarding prior litigation and the unregistered sale of equity securities.
Key Financial Metrics and Transactions
- Settlement Liability: The Company agreed to pay a total of $6,010,000 to resolve disputes with Dr. Elizabeth Pritts and the Elizabeth Pritts Revocable Living Trust.
- Cash Paid to Date: $1,755,000 has been paid as of September 30, 2025 (comprising an initial $1,000,000 and a $755,000 payment due on the filing date).
- Future Obligations: Remaining payments total $4,255,000, scheduled as follows: $755,000 (Dec 31, 2025), $1,000,000 (Mar 31, 2026), $2,000,000 (Jun 30, 2026), and $500,000 (Dec 31, 2026).
- Equity Financing: The Company raised $400,000 in cash through the sale of 400 shares of Series C-2 Convertible Preferred Stock to an existing institutional investor.
- Conversion Price Adjustment: The exercise of the Additional Investment Right adjusted the conversion price of the C-2 Preferred to $0.7141 per share.
Material Changes and Legal Developments
The filing resolves a complaint filed on May 7, 2025, in the Circuit Court of Wisconsin, Dane County. The lawsuit alleged breach of contract, tortious interference, and unjust enrichment related to the acquisition of Wisconsin Fertility Institute. The settlement agreement terminates all employment, consulting, and related agreements with Dr. Pritts and releases all claims between the parties. A consent judgment was entered to enforce the settlement terms.
Outlook, Risks, and Management Commentary
The settlement includes a provision requiring the Company to provide its subsidiary, Wood Violet Fertility LLC, with 25% of all gross funding proceeds above $2,000,000 raised within any six-month period to accelerate settlement payments. The filing does not provide specific forward-looking financial guidance, revenue projections, or liquidity metrics beyond the settlement terms. The primary risk identified is the potential for a consent judgment to be entered if the Company breaches the Settlement Agreement.
Investor Verification Checklist
- Verify the Company's current cash position and ability to meet the $4,255,000 in scheduled future settlement payments.
- Review the impact of the 25% gross funding proceeds clause on future capital raising efforts and subsidiary operations.
- Confirm the dilution impact of the Series C-2 Convertible Preferred Stock at the new conversion price of $0.7141 per share.
- Examine the full text of the Settlement Agreement (Exhibit 10.1) for specific indemnification and release terms.